Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design - Concepedia

Concepedia

Publication | Open Access

Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design

DOI Full Paper Access

36

Citations

25

References

2021

Year

Liron Walsh, John F. Reilly, C. Cornwall, Gregory Gaich, Debbie S. Gipson, Hiddo J.L. Heerspink, Leslie P. Johnson, Howard Trachtman, Katherine R. Tuttle, Youssef Farag,

Kidney International Reports

References

	Year	Citations

Page 1